Levodopa Pregnancy and Breastfeeding Warnings
Levodopa is also known as: Dopar, Larodopa
Levodopa Pregnancy Warnings
Levodopa has not been formally assigned to a pregnancy category. However, some of the commercially available formulations of levodopa-carbidopa have been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of visceral and skeletal malformations in rabbits at doses 5 to 20 times the maximum recommended human dose of levodopa-carbidopa. There are no controlled data in human pregnancy. Two reports have described three patients who received levodopa or levodopa-carbidopa throughout pregnancy without evidence of fetal harm. Levodopa should only be given in human pregnancy when benefit outweighs risk.
One study has reported that single oral doses of levodopa administered to pregnant women result in decreased plasma renin activity, decreased plasma aldosterone and decreased plasma prolactin.
Levodopa Breastfeeding Warnings
There are no data on the excretion of levodopa into human milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
References for pregnancy information
- "Product Information. Sinemet CR (carbidopa-levodopa)." Dupont Pharmaceuticals, Wilmington, DE.
- "Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals, Wilmington, DE.
References for breastfeeding information
- "Product Information. Larodopa (levodopa)." Roche Laboratories, Nutley, NJ.